Citius Pharmaceuticals, Inc.
CTXR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CTXR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CTXR
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing first-in-class critical care products, with a lead commercial product LYMPHIR and a pipeline including Mino-Lok and Halo-Lido.
Key risk: Cash burn and negative working capital
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Citius Pharmaceuticals, Inc..
Similar companies
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing first-in-class critical care products, with a lead commercial product LYMPHIR and a pipeline including Mino-Lok and Halo-Lido.
- Citius began commercial distribution of LYMPHIR in December 2025 and reported product revenues of $7.1 million for the nine months ended June 30, 2026 [sec_mda · as of 2026-08-14].
- As of June 30, 2026, the company had cash and equivalents of $17.0 million, an accumulated deficit of approximately $277.1 million, and negative working capital of approximately $8.3 million [sec_mda · as of 2026-08-14].
- The company's pipeline includes Mino-Lok (antibiotic lock solution) and Halo-Lido (topical anesthetic/hemorrhoid treatment), both reformulations of previously approved drugs [sec · filed 2026-05-22].
- In April 2026, Citius closed a registered direct offering raising net proceeds of $4.45 million [sec_mda · as of 2026-08-14].
- The company's strategy focuses on products with intellectual property and regulatory exclusivity protection that offer competitive advantages over existing therapies [sec · filed 2026-05-22].
What works
- LYMPHIR has generated initial commercial revenue with repeat orders and an initial shipment to Europe in April 2026, indicating early market acceptance [sec_mda · as of 2026-08-14].
- The company's focus on reformulations of previously approved drugs with existing safety data may reduce development and clinical risk [sec · filed 2026-05-22].
- Gross profit margins on LYMPHIR were approximately 77% for the nine months ended June 30, 2026, suggesting favorable unit economics [sec_mda · as of 2026-08-14].
What to weigh
- The company had an accumulated deficit of $277.1 million and negative working capital of $8.3 million as of June 30, 2026, reflecting ongoing cash burn [sec_mda · as of 2026-08-14].
- Net cash used in operations was approximately $23.0 million for the nine months ended June 30, 2026, with limited revenue from LYMPHIR to date [sec_mda · as of 2026-08-14].
- The company's primary source of cash has been financing activities, and it may need additional capital to fund operations and pipeline development [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
LYMPHIR commercial launch generated first revenue in December 2025
“Citius Pharmaceuticals reported its first revenue following the launch of LYMPHIR.”
News · February 13, 2026
Product revenues for nine months ended June 30, 2026 were $7.1M
“Product revenues for the nine months ended June 30, 2026 were $ 7,105,197”
SEC MD&A · August 14, 2026
Company strategy focuses on reformulations of approved drugs
“New formulations of previously approved drugs with substantial existing safety and efficacy data are a core focus.”
SEC filings · May 22, 2026
Risks & what to watch (4)›
Key risks
- Cash burn and negative working capital — As of June 30, 2026, negative working capital of $8.3M and net cash used in operations of $23.0M in nine months [sec_mda · as of 2026-08-14]
- Dependence on LYMPHIR commercial success — Revenue is limited to LYMPHIR launch; future revenue growth depends on market acceptance and repeat orders [sec_mda · as of 2026-08-14]
- Accumulated deficit and financing needs — Accumulated deficit of $277.1M; primary cash source is financing, with no assurance of future capital availability [sec_mda · as of 2026-08-14]
- Pipeline development risk — Mino-Lok and Halo-Lido are still in development; failure to obtain regulatory approval would impair pipeline value [sec · filed 2026-05-22]
What to watch
- LYMPHIR revenue growth and repeat order trends, especially from European markets following initial shipment in April 2026 [sec_mda · as of 2026-08-14]
- Cash runway and potential need for additional financing given negative working capital and operating cash burn [sec_mda · as of 2026-08-14]
- Progress of Mino-Lok and Halo-Lido clinical development and regulatory milestones [sec · filed 2026-05-22]
- Next-stage development decisions for the combination study of pembrolizumab with other agents in gynecologic cancers [sec_mda · as of 2026-08-14]
Sources: News · SEC filings · SEC MD&A · Generated August 22, 2026 · How we verify sources →
Run Citius Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Citius Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
8.6 months
D/E 1.00 · 0% dilution
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
35
Total value held
$916K
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 335,476 | $302K |
| geode capital management, llc | 246,158 | $222K |
| vanguard fiduciary trust co | 77,755 | $70K |
| blackrock, inc. | 69,851 | $63K |
| jane street group, llc | 46,423 | $42K |
| northern trust corp | 43,974 | $40K |
| susquehanna international group, llp | 36,838 | $33K |
| citadel advisors llc | 29,100 | $26K |
| state street corp | 23,271 | $21K |
| xtx topco ltd | 21,295 | $19K |
Showing top 10 of 35 institutional holders of Citius Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 19.5%
- Days to cover
- 6.3
- Shares short
- 5,263,532
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CTXR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Citius Pharmaceuticals, Inc.?
Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing first-in-class critical care products, with a lead commercial product LYMPHIR and a pipeline including Mino-Lok and Halo-Lido.
What is Citius Pharmaceuticals, Inc.'s lead drug candidate?
Citius Pharmaceuticals, Inc.'s most advanced tracked candidate is LYMPHIR (Approved) for Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL).
Who is the CEO of Citius Pharmaceuticals, Inc.?
Mr. Leonard L. Mazur is the chief executive officer of Citius Pharmaceuticals, Inc. (CTXR).
Where is Citius Pharmaceuticals, Inc. headquartered?
Citius Pharmaceuticals, Inc. (CTXR) is headquartered in Cranford, NJ, United States.
What therapeutic areas does Citius Pharmaceuticals, Inc. focus on?
Citius Pharmaceuticals, Inc. develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.